Clinical Trial

A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated January 13, 2023 (before its estimated December 30, 2024 completion). Its status may not reflect the trial's current state.
Summary
HS-10382 is a small molecular, oral potent, allosteric inhibitor. By binding a myristoyl site of the BCR-ABL1 protein, HS-10382 locks BCR-ABL1 into an inactive conformation. The purpose of this study is to investigate the safety/tolerability and the pharmacokinetic(PK) profile of HS-10382 in patients with chronic myeloid leukemia (CML). Anti-CML activity will also be investigated in this study.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-05-06.
Status change: Not Yet Recruiting → Recruiting 2023-01-12
Trial Details
NCT Number NCT05367700
Lead Sponsor Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions CML, Chronic Phase, CML, Accelerated Phase
Enrollment 108 participants
Start Date 2022-04-28
Primary Completion 2024-12-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2023-01-13